Loading…
BioAge Labs, Inc. is projected to rise to $19.43 by 2027, a +15% move from its current price of $16.95. BIOA is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $16.26 | $16.96 | $17.69 | +0.05% |
| May 30 | $15.99 | $16.97 | $18.01 | +0.11% |
| May 31 | $15.78 | $16.98 | $18.26 | +0.16% |
| Jun 1 | $15.61 | $16.99 | $18.48 | +0.21% |
| Jun 2 | $15.47 | $17.00 | $18.67 | +0.27% |
| Jun 3 | $15.34 | $17.00 | $18.85 | +0.32% |
| Jun 4 | $15.22 | $17.01 | $19.02 | +0.37% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $15.22 | $17.01 | $19.02 | +0.37% |
| Week 2 | $14.59 | $17.08 | $19.99 | +0.75% |
| Week 3 | $14.13 | $17.14 | $20.79 | +1.13% |
| Week 4 | $13.77 | $17.20 | $21.50 | +1.50% |
| Week 5 | $13.46 | $17.27 | $22.16 | +1.88% |
| Week 6 | $13.19 | $17.33 | $22.78 | +2.26% |
| Week 7 | $12.95 | $17.40 | $23.37 | +2.65% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
BioAge Labs, Inc., a clinical-stage biopharmaceutical company, develops therapeutic product candidates for metabolic diseases. The company's technology platform and differentiated human datasets that allows users to identify targets based on insights into molecular changes that drive aging.
Its lead product candidate includes BGE-102, an orally available brain-penetrant small-molecule NLRP3 inhibitor which is in Phase 1 clinical trail for the treatment of atherosclerotic cardiovascular disease, as well as for the treatment of diabetic macular edema and geographic atrophy; and develops APJ agonists for obesity, including programs targeting both oral and parenteral administration.
The company has collaboration agreement with Novartis Pharma AG to identify and validate novel therapeutic drug targets by investigating the biological mechanisms that drive aging and mediate diseases related to aging and mediate. BioAge Labs, Inc. was incorporated in 2015 and is headquartered in Emeryville, California.
BioAge Labs, Inc. (BIOA) is currently trading at $16.61 per share and has a market cap of $738.36M, ranking 2746.
The stock operates in the Healthcare sector and carries a bullish technical sentiment.
A major floor 23.1% below — a decisive break under it would weaken the trend.
The nearest floor, 9.5% below — buyers have tended to step in here.
The nearest ceiling, 15.7% above — a clean break opens room to run.
A major ceiling 31.7% above — clearing it would confirm fresh momentum.
Key BIOA support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of BIOA market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $16.52 | Buy | $16.66 | Buy |
| MA 10 | $16.98 | Sell | $16.85 | Buy |
| MA 20 | $17.21 | Sell | $17.13 | Sell |
| MA 50 | $17.52 | Sell | $17.54 | Sell |
| MA 100 | $18.53 | Sell | $16.79 | Buy |
| MA 200 | $12.97 | Buy | $14.47 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 48.05 | Neutral |
| Stoch RSI (14) | 49.78 | Neutral |
| CCI (20) | -20.77 | Neutral |
| Williams %R (14) | -57.63 | Info |
| MACD (12,26,9) | -0.09 | Sell |
| ROC (12) | -5.78 | Sell |
| Bollinger %B (20,2) | 0.43 | Neutral |
| Stochastic %K (14) | 42.37 | Neutral |
| TRIX (15) | -0.18 | Sell |
| Awesome (5,34) | -0.83 | Sell |
| Ultimate (7,14,28) | 43.91 | Neutral |
| Momentum (10) | -1.24 | Sell |
| Aroon Osc (25) | -76.00 | Sell |
| Hull MA (9) | 16.50 | Buy |
| ADX (14) | 10.89 | Neutral |
| ATR (14) | 0.64 | Info |
The 30-day technical picture shows bullish sentiment with RSI14 at 50. The stock trades above the SMA200 at $12.85 but below the SMA50 at $17.67, and it faces a defined near-term band between support and resistance.
Key levels to watch are support at $15.34 and resistance at $19.61. The 30-day price range runs from $12.47 to $22.12, indicating meaningful near-term volatility.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $12.62 | $16.95 | $21.29 | 0% | Neutral | |
| $14.60 | $19.43 | $27.80 | +15% | Neutral | |
| $14.80 | $20.60 | $31.03 | +22% | Bullish | |
| $17.06 | $24.66 | $38.65 | +46% | Bullish | |
| $22.76 | $34.04 | $55.16 | +101% | Bullish | |
| $22.47 | $34.69 | $57.86 | +105% | Bullish | |
| $23.12 | $36.77 | $62.94 | +117% | Bullish | |
| $23.94 | $39.19 | $68.65 | +131% | Bullish | |
| $21.59 | $36.32 | $65.00 | +114% | Bullish | |
| $28.70 | $49.58 | $90.49 | +192% | Bullish | |
| $34.48 | $67.47 | $133.63 | +298% | Bullish | |
| $61.02 | $135.60 | $301.73 | +700% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $12.62 | $16.95 | $20.13 | +0.00% |
| June 2026 | $15.06 | $17.90 | $21.93 | +5.61% |
| July 2026 | $14.78 | $17.79 | $22.25 | -0.60% |
| August 2026 | $14.01 | $17.05 | $21.65 | -4.18% |
| September 2026 | $14.02 | $17.20 | $22.13 | +0.90% |
| October 2026 | $14.02 | $17.35 | $22.56 | +0.83% |
| November 2026 | $13.21 | $16.46 | $21.62 | -5.13% |
| December 2026 | $12.81 | $16.06 | $21.29 | -2.41% |
Click any year to see its month-by-month BIOA forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
By 2026, BIOA could reach as high as $21.29, with a base case around $16.95 and support toward $12.62 — roughly 0% from $16.95. Price action looks broadly range-bound.
Expect BIOA to range from $14.60 to $27.80 through 2027. The $19.43 average target implies a +15% move from current prices. That is up +15% on the projected 2026 average. A consolidation phase looks the most probable path here.
The BIOA price prediction for 2028 points to an average of $20.60 (low $14.80, high $31.03) — a potential gain of +22% on today's $16.95. Momentum favours further upside here.
In 2029, BIOA is projected to trade between $17.06 and $38.65, averaging $24.66 — a potential gain of +46% from today's $16.95. That is up +20% on the projected 2028 average. Buyers look set to stay in control over this stretch.
BioAge Labs, Inc.'s 2030 outlook centres on $34.04, within a $22.76 to $55.16 range. That is up +38% on the projected 2029 average. That marks a +101% change versus current levels. Momentum favours further upside here.
By 2031, BIOA could reach as high as $57.86, with a base case around $34.69 and support toward $22.47 — roughly +105% from $16.95. Buyers look set to stay in control over this stretch.
Expect BIOA to range from $23.12 to $62.94 through 2032. The $36.77 average target implies a +117% move from current prices. That is up +6% on the projected 2031 average. Momentum favours further upside here.
The BIOA price prediction for 2033 points to an average of $39.19 (low $23.94, high $68.65) — a potential gain of +131% on today's $16.95. Buyers look set to stay in control over this stretch.
In 2034, BIOA is projected to trade between $21.59 and $65.00, averaging $36.32 — a potential gain of +114% from today's $16.95. That is -7% versus the projected 2033 average. Momentum favours further upside here.
BioAge Labs, Inc.'s 2035 outlook centres on $49.58, within a $28.70 to $90.49 range. That is up +36% on the projected 2034 average. That marks a +192% change versus current levels. Buyers look set to stay in control over this stretch.
By 2040, BIOA could reach as high as $133.63, with a base case around $67.47 and support toward $34.48 — roughly +298% from $16.95. Momentum favours further upside here.
Expect BIOA to range from $61.02 to $301.73 through 2050. The $135.60 average target implies a +700% move from current prices. That is up +101% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in BIOA today (≈ 58.99705 BIOA) could be worth
$8,000.12
+$7,000.12 (+700%) by 2050 · US Dollar
Based on the average projected BIOA price of $135.6 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in BIOAwould be worth at today's price.
$1,000 invested in BIOA on May 27, 2025 (≈ 253.164554 BIOA) would be worth
$4,291.14
+$3,291.14 (+329.1%) today · 4.29× · US Dollar
Based on a BIOA entry price of $3.95 vs. today's $16.95.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $16.11 | $1,052.14 | +5.2% |
| 1 month ago | $18.06 | $938.54 | -6.1% |
| 3 months ago | $22.32 | $759.41 | -24.1% |
| 6 months ago | $9.49 | $1,786.09 | +78.6% |
| 1 year ago | $3.95 | $4,291.14 | +329.1% |
| All time (1.7y) ago | $18.31 | $925.72 | -7.4% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our BIOA forecast.
Our base-case forecast reaches $34.00 around 2030.
Implied market cap at $34.00: $1.51B
The multi-year forecast depicts a bullish trajectory with rising average prices and sizable ROIs across the horizon.
In 2027 the average price is forecast at $19.16 with a 15.4% ROI; by 2030 the average rises to $33.96 with a 104.5% ROI; 2031 sees an average of $34.29 and a 106.4% ROI, and 2032 at $36.60 with a 120.3% ROI. By 2033 the average is $38.91 (134.2% ROI) and 2035 at $49.99 (201% ROI).
Looking further, 2040 shows an average of $66.64 with a 301.2% ROI and a max of $133.76; 2050 projects an average of $136.40 with a max of $308.17 and a 721.2% ROI. These figures suggest a substantial long-run upside, though they are estimates and not guarantees.
Tap a question to reveal the answer.
Avg $33.96; min $22.48; max $55.55; ROI 104.5%.
The forecast shows a bullish path with rising averages and ROIs across multiple years (e.g., 2027 avg $19.16, 2030 avg $33.96, 2050 avg $136.40 and up to 721.2% ROI). These are estimates, not guarantees.
Yes, the forecast max by 2040 is $133.76, with 2040 ROI at 301.2%; 2035 max is $92.34. This implies crossing $100 could occur by 2040 in the max scenario.
Current price $16.61; market cap $738.36M.
Avg $19.16; ROI 15.4%.
BioAge Labs, Inc. Community Discussion
0Share your BioAge Labs, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.